Parkinson's Disease Drug Development Enters 'Era of Diversification' After Past Failures
The pipeline for Parkinson's disease therapies is undergoing a significant shift, moving into an 'era of diversification' following numerous clinical failures. Drugmakers are now exploring a wider range of biomarkers and biological processes beyond traditional targets like alpha-synuclein, which has been the focus of many unsuccessful trials. Jefferies analysts project the Parkinson's market could reach $8 billion by 2035, highlighting it as a major untapped opportunity in neuroscience. Despite this potential, the disease's complexities—including late diagnosis, slow progression, and varied patient biology—have led to a long list of clinical setbacks. While some companies, like Roche, continue to pursue alpha-synuclein targets with late-stage candidates such as prasinezumab, others are investigating new avenues. These include targeting inflammation via the NLRP3 protein, with companies like AC Immune and Eli Lilly involved, and continuing research into LRRK2 inhibitors by Denali and others, despite previou... 
